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Skin infections caused by antibiotic resistant Staphylococcus aureus are a signiﬁcant
health problem worldwide; often associated with high treatment cost and mortality rate.
Complex natural products like New Zealand (NZ) manuka honey have been revisited and
studied extensively as an alternative to antibiotics due to their potent broad-spectrum
antimicrobial activity, and the inability to isolate honey-resistant S. aureus. Previous studies
showing synergistic effects between manuka-type honeys and antibiotics have been
demonstrated against the growth of one methicillin-resistant S. aureus (MRSA) strain. We
have previously demonstrated strong synergistic activity between NZ manuka-type honey
and rifampicin against growth and bioﬁlm formation of multiple S. arueus strains. Here,
we have expanded our investigation using multiple S. aureus strains and four different
antibiotics commonly used to treat S. aureus-related skin infections: rifampicin, oxacillin,
gentamicin, and clindamycin. Using checkerboard microdilution and agar diffusion assays
with S. aureus strains including clinical isolates and MRSA we demonstrate that manuka-
type honey combined with these four antibiotics frequently produces a synergistic effect.
In some cases when synergism was not observed, there was a signiﬁcant enhancement
in antibiotic susceptibility. Some strains that were highly resistant to an antibiotic when
present alone become sensitive to clinically achievable concentrations when combined
with honey. However, not all of the S. aureus strains tested responded in the same way to
these combinational treatments. Our ﬁndings support the use of NZ manuka-type honeys
in clinical treatment against S. aureus-related infections and extend their potential use as
an antibiotic adjuvant in combinational therapy. Our data also suggest that manuka-type
honeys may not work as antibiotic adjuvants for all strains of S. aureus, and this may help
determine the mechanistic processes behind honey synergy.
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INTRODUCTION
Staphylococcus aureus is amajor causative agent of chronic wounds
such as diabetic foot ulcers, venous leg ulcers, and pressure
ulcers (Eady and Cove, 2003; Dowd et al., 2008; DeLeo and
Chambers, 2009). These slow- or non-healing wounds pose a
signiﬁcant risk of sepsis and can result in invasive inﬂamma-
tory disease such as infective endocarditis, which is associated
with high mortality and morbidity (Orsi et al., 2002). In addi-
tion methicillin-resistant S. aureus (MRSA) strains have become
resistant to most antibiotics both in the hospital and in the
community (Zetola et al., 2005; Kardas-Sloma et al., 2011). One
approach to combat the development of resistance is combina-
tion drug treatment (Greco et al., 1995). This improves treatment
efﬁcacy and enhances the value of existing antimicrobials in the
absence of new drug development. In some cases, combina-
tions of antimicrobials are synergistic, where the effect of two
drugs in combination is signiﬁcantly greater than the sum of
each drug alone. This has the additional beneﬁts of reducing
both the treatment costs and the risk of possible side effects due
to the lower concentrations of both agents used (Leibovici et al.,
2010).
Naturally derived compounds like honey are gaining popu-
larity as an alternative to antimicrobial compounds (Allen et al.,
1991; Bogdanov et al., 2008). Honey is a natural product that
has been applied to the topical treatment of infected chronic
wounds (Molan and Cooper, 2000; Molan, 2006). Honey dress-
ings and wound gels have been licensed by health authorities and
are available to health professionals in many countries. Honey
has a complex chemistry (Adams et al., 2008; Mavric et al., 2008),
with established, broad-spectrum antibacterial activity against a
diverse array of microorganisms, including those that are com-
monly associated with chronic wounds such as S. aureus and
Pseudomonas aeruginosa (Blair et al., 2009; Henriques et al., 2010;
Packer et al., 2012; Lu et al., 2013). NZ manuka honey, derived
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from nectar collected by honeybees (Apis mellifera) foraging on
Leptospermum scoparium, is the major honey in clinical use today.
Although the precise antimicrobial action of honey is unclear, sev-
eral components have been identiﬁed that contribute toward its
antimicrobial activity, including high sugar content, low water
activity, low pH, and the formation of hydrogen peroxide upon
dilution. In addition, methylglyoxal (MGO) has been identiﬁed as
the dominant antimicrobial component of manuka honey (Adams
et al., 2008; Mavric et al., 2008). Published clinical cases suggest
that, in addition to killing infecting bacteria, medicinal manuka
honeys promote chronic and acute wound healing by stimulating
the host immune system (Gannabathula et al., 2012). However,
honey represents a ‘challenge to the norm’ for healthcare work-
ers and remains under-utilized in mainstream healthcare, often
only used as a last line treatment when other therapies have
failed. This is partly due to the lack of comprehensive scien-
tiﬁc evidence supporting its clinical use (Cooper and Jenkins,
2012).
Bacteria appear unable to develop resistance to manuka honey,
even when sub-inhibitory concentrations are used (Blair et al.,
2009; Cooper et al., 2010). This is in contrast to antibiotics, where
resistance is readily induced with sub-inhibitory exposure (Blair
et al., 2009; Packer et al., 2012). This lack of resistance is probably
due to the multiple antibacterial properties of honey that over-
whelm bacterial stress responses (Blair et al., 2009; Jenkins et al.,
2011, 2014). Manuka honey therefore offers a promising alterna-
tive for topical use, both as a single multi-component agent in its
own right as well as in combination with antibiotics. Synergis-
tic interactions between manuka honey and antibiotics, including
oxacillin (Jenkins and Cooper, 2012b), tetracycline, imipenem,
and mupirocin against the growth of a MRSA strain, EMRSA-15,
have been reported (Jenkins and Cooper, 2012a). In our previous
study we also found strong synergistic activity between manuka
honey and rifampicin against multiple S. aureus strains, including
clinical isolates and MRSA strains (Müller et al., 2013).
In this study we have expanded our investigation of honey syn-
ergy to include four antibiotics that are commonly administered to
patients with staphylococcal infections: rifampicin, clindamycin,
gentamicin, and oxacillin (Rayner and Munckhof, 2005), and have
included a range of S. aureus strains including clinical isolates
and MRSAs. Qualitative agar diffusion assays were performed,
and checkerboard microdilution assays were used to determine
if these combinations were quantitatively additive or synergis-
tic against planktonic growth of S. aureus. The aims were: (1)
to identify further novel honey-antibiotic therapies for staphy-
lococcal infections; and (2) to determine whether antibiotic or
strain-speciﬁc responses might occur. In addition, since bioﬁlms
are recognized to play a signiﬁcant role in chronic wound infec-
tions (Percival et al., 2012), we tested whether synergy extends
to the prevention of bioﬁlm formation on an abiotic surface.
We show that the combination of rifampicin and manuka honey
yields the best result, being synergistic against all tested strains for
both the inhibition of planktonic growth as well as the prevention
of S. aureus bioﬁlms. This was followed by the antibiotics clin-
damycin and oxacillin, which were synergistic with manuka honey
for most strains, while additivity was observed with gentamycin
and manuka honey. Responses were observed to be strain- and
antibiotic-speciﬁc, indicating that synergy is not a generic process
induced by honey, such as a general weakening of cells, but tar-
gets speciﬁc processes that may or may not enhance antimicrobial
action. Our results support the use of manuka honey in combina-
tional therapy of chronic wounds with antibiotics, and argues for
a wider acceptance of honey in mainstream medicine.
MATERIALS AND METHODS
BACTERIAL STRAINS, MEDIA, AND ANTIMICROBIAL AGENTS
Staphylococcus aureus isolates included laboratory strain
NCTC8325 and clinical isolates 04-227-3567 (non-MRSA), MW2
(MRSA; also known as USA400 and CA-MRSA; kindly provided
by Dr. Barry Kreiswirth, Public Health Research Institute Center,
New Jersey Medical School-Rutgers, The State University of New
Jersey, USA) and RPAH18 (designated AUS-2 multi-resistance
MRSA strain; and kindly provided by Dr. Jon Iredell, Westmead
Hospital, Sydney, NSW, Australia). All planktonic growth and
bioﬁlm prevention assays were carried out using tryptone soya
broth (TSB;Oxoid). Agar diffusion tests used TSB agar (TSB + 1%
agar; Sigma–Aldrich) in 90 × 15 mm petri dishes. Antibiotics
(rifampicin, oxacillin sodium salt, clindamycin hydrochloride, and
gentamicin sulfate solution) were purchased from Sigma–Aldrich.
Two manuka-type honeys were used in this study: (1)
unprocessed manuka honey sourced from L. scoparium plan-
tations in Hokianga, New Zealand (MGO: 958 mg/kg; H2O2:
0.34 μmol/h); and (2) commercially available manuka honey
(L. scoparium + Kunzea ericoides) in a proprietary formulation
(Medihoney, MGO: 776 mg/kg; H2O2: 0.31 μmol/h). Both were
provided by Comvita Ltd, New Zealand and were stored in the
dark at 4◦C. The concentrations of two major antimicrobial com-
ponents in these NZ honeys, MGO, and hydrogen peroxide (as a
production rate) were tested for this study and are equivalent to
previously reported levels (Lu et al., 2014). In brief, MGO levels
were analyzed against di-hydroxyacetone and expressed as mil-
ligram (mg) of MGO per kilogram (kg) of honey. The rate of
production of H2O2 levels is expressed as micromole per hour
(μmol/h) in 1 ml of 10% honey. Both honeys were diluted fresh
for use in every assay. Honey concentrations are reported in this
study as%weight/volume (w/v). A sugar solution comprising 45%
glucose, 48% fructose, and 1% sucrose (w/v) was made to be iso-
tonic with honey, and was also used to examine the effect of sugar
alone or in combination with the antibiotics.
DETERMINATION OF THE MINIMUM INHIBITORY CONCENTRATION
(MIC) OF ANTIMICROBIAL AGENTS
Microdilution growth assays were used to assess the minimum
inhibitory concentration (MIC) of antibiotics and honey against
S. aureus strains. Routine static growth conditions were used
against S. aureus clinical isolates 04-227-3567,MW2, and RPAH18
according to Clinical and Laboratory Standards Institute (CLSI)
recommendations (CLSI, 2012), while shaking culture conditions
were used for S. aureus strain NCTC8325 as its very strong ten-
dency to form bioﬁlms on abiotic surfaces under static growth
conditions limited detection of planktonic growth in the liquid
media phase. For both assays, diluted overnight bacterial cul-
ture (107 CFU/mL, determined by CFU counting) was used to
inoculate wells of a sterile 96-well ﬂat-bottomed plate. Various
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concentrations of honeys or antibiotics were added to the desig-
nated wells by twofold serial dilutions with TSB growth media to
a ﬁnal volume of 150 μL. Untreated controls were also included.
In the static growth assay, the plates were brieﬂy shaken to mix the
contents of each well and the optical density (OD) of each well was
measured at 590 nm in a Synergy HT BioTek plate reader (BioTek
Instruments Inc., USA). The plate was then incubated without
shaking in a 37◦C in a humidiﬁed incubator for 24 h, and the OD
of each well was measured again at the end of incubation. The OD
difference between the two time points was used to measure cell
growth. In the shaking culture assay the plate was incubated in the
same microtiter plate reader at 37◦C with continuous moderate
shaking to prevent bioﬁlm formation (1800 rpm, amp. 0.549 mm
x-axis) for 24 h, and was programmed to measure the OD hourly
at 595 nm (Gen5 software, BioTek Instruments Inc., USA). For
both growth assays, the MIC was deﬁned as the lowest concentra-
tion of antimicrobial agent that inhibited 99% growth of S. aureus
when compared to the untreated control.
AGAR DIFFUSION TESTS TO ASSESS ANTIBIOTIC-HONEY INTERACTION
AGAINST S. aureus
Fifty microliter aliquots of 109 CFU/mL overnight culture of each
of the S. aureus strains were spread uniformly onto TSB agar plates
with or without 5% honey. This was previously determined to be
a non-lethal, sub-inhibitory concentration of honey under these
conditions (Müller et al., 2013). Paper disks impregnatedwith 4μg
of each antibiotic were then placed onto the agar surface. Inhibi-
tion zones were measured after 24 h incubation at 37◦C. Assays
were performed three separate times induplicate. Todetermine the
effect of 5% honey alone on bacterial growth, 20 μL of overnight
culture (1 × 109 CFU/mL) was diluted in 180 μL of PBS, followed
by further serial dilutions (10−1–10−8). 20μLof each dilutionwas
then spotted onto a freshly prepared TSA plate with or without 5%
honey (in triplicate). Colonies were counted after 24 h incubation
at 37◦C and CFUs were determined. As a control for the effect
of sugar on inhibition of cell growth, a sugar solution made to
be isotonic with honey was also used at 5% in combination with
antibiotics.
Differences among the treatments (e.g., antibiotic alone,
manuka honey-antibiotic, Medihoney-antibiotic and sugar
solution-antibiotic) were assessed by one-way analysis of variance
(ANOVA) with signiﬁcance set at p ≤ 0.05. Dunnett’s test was
performed post hoc for all assays where p < 0.05. This test further
determines which of the three mean values of combination treat-
ments (e.g., manuka, Medihoney, or sugar solution) is different
from the antibiotic treatment alone. Statistical analyses were per-
formed using GraphPad Prism ver.5.0c (Graphpad Software, San
Diego, CA, USA).
DETERMINATION OF MINIMUM BIOFILM INHIBITORY
CONCENTRATION (MBIC) OF ANTIMICROBIAL AGENTS
Minimum bioﬁlm inhibitory concentrations (MBICs) for the
honey and antibiotics against S. aureus were determined using
microdilution assays with crystal violet staining. Plates were pre-
pared as for the MIC assays. Following incubation, the liquid from
each well was carefully removed with a pipette and the wells were
washed gently by rinsing with phosphate buffered saline (PBS)
twice to remove loosely attached planktonic cells. The remain-
ing bioﬁlms were dry-ﬁxed onto the plates by air-drying at 65◦C
for 1 h and then stained with 0.2% crystal violet solution for
1 h at room temperature. The excess crystal violet solution was
decanted and the plates were rinsed with sterile reverse osmo-
sis (RO) water, brieﬂy dried, and the stained bioﬁlms in each
well were solubilized with 30% acetic acid. The OD of each well
was measured at 595 nm using an automated Vmax plate reader
(Molecular Devices, USA). OD readings were normalized to the
untreated bioﬁlm biomass and expressed as a percentage. MBICs
were deﬁned as the lowest concentration of antimicrobial agent
that completely prevented the establishment of a bioﬁlm (0%
bioﬁlm biomass) in the microtiter-plate well compared to the
untreated control.
For checkerboard microdilution assays, each pair of antimi-
crobial agents (honey and antibiotic) were added across the x
and y dimensions of a 96-well plate by twofold serial dilution
with TSB growth media. Concentrations ranged from 0.03 to
1 × MIC for each antibiotic and from 2 to 32% for each honey.
Each combination was repeated in the adjacent horizontal wells
to provide technical duplicates. An overnight culture of S. aureus
was then added to each well to give a ﬁnal inoculum of approxi-
mately 107 CFU/mL. Crystal violet staining of adherent bioﬁlm
was performed as described above. All checkerboard microdi-
lution assays were repeated two times on two different days to
provide experimental replicates.
Synergy was assessed using the fractional inhibition con-
centration index (FICI). For inhibition of planktonic growth,
FICI = (MIC of antibiotic in combination/MIC of antibiotic
alone) + (MIC of honey in combination/MIC of honey alone;
Eliopoulos and Moellering, 1996); FICI for the inhibition of
bioﬁlm formation was calculated similarly, with MBIC replacing
MIC in the formula. Synergy was deﬁned as FICI ≤ 0.5, no inter-
action was deﬁned as FICI > 0.5–4, and antagonism was deﬁned
as FICI > 4 (Odds, 2003).
RESULTS
MINIMUM INHIBITORY CONCENTRATIONS OF HONEYS AND
ANTIBIOTICS AGAINST S. aureus STRAINS DURING PLANKTONIC
GROWTH
The in vitro antibacterial activity against planktonic growth for
Medihoney, manuka honey, and for each of the antibiotics was
established by determining the MICs against the various S. aureus
strains. The results are summarized in Table 1.
For both manuka honey and Medihoney, the MICs for all
strains were 8% (w/v) and are consistent with our previous stud-
ies (Blair et al., 2009; Lu et al., 2013, 2014; Müller et al., 2013).
The non-MRSA strains (NCTC8325 and 04 227-3567) had similar
MICs for all four antibiotics (rifampicin, oxacillin, clindamycin,
and gentamicin), which ranged from 0.04 to 0.625 μg/mL. MRSA
strains (RPAH18 and MW2) displayed a more resistant proﬁle,
with RPAH18 being sensitive to only one of the four antibiotics
(rifampicin) andMW2 sensitive to three (rifampicin, clindamycin,
and gentamicin). These antibiotic MICs are consistent with those
reported in the literature for S. aureus (Porthouse et al., 1976;
Maduri Traczewski et al., 1983; Smith et al., 2009; Bauer et al.,
2013).
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Table 1 | Minimum inhibitory concentrations (MICs) of antimicrobial agents against Staphylococcus aureus strains.
Strains Minimum inhibitory concentrations
Manuka honey % (w/v) Medihoney % (w/v) Rifampicin (μg/ml) Clindamycin (μg/ml) Gentamicin (μg/ml) Oxacillin (μg/ml)
NCTC8325 8 8 0.04 0.3 0.625 0.25
RPAH181,2 8 8 0.08 >20 >20 >20
MW21,2 8 8 0.04 0.3 0.6 >20
04 227–35672 8 8 0.04 0.3 0.5 0.25
1MRSA strain;
2Clinical isolate.
MOST HONEY–ANTIBIOTIC COMBINATIONS INTERACT POSITIVELY TO
INHIBIT THE GROWTH OF S. aureus
Agar diffusion tests were performed to visualize the possible inter-
actions between manuka honey or Medihoney and each antibiotic
against each S. aureus strain (Figure 1). Sensitivity was measured
based on the diameter of the zone of growth inhibition for antibi-
otics alone, or in combination with 5% (sub-MIC) manuka honey
or Medihoney. A sugar solution made to be isotonic with honey
was also used at 5% to examine the sole effect of sugar in combina-
tion with antibiotics. Additive effects are indicated by an increase
in diameter of the inhibition zone with both antibiotics and honey
compared to the use of an antibiotic alone.
For rifampicin, both MRSA and non-MRSA strains were
sensitive and showed additive effects with the addition of 5%
Medihoney or manuka honey, where inhibition zones were
approximately doubled, consistent with our previous report
(Müller et al., 2013). A similar effect was observed for oxacillin,
where sensitive strains showed an approximate doubling of
the inhibition zone with the addition of either honey, and
resistant strains became sensitive with ∼30 mm zones of inhi-
bition. This agrees with a recent report where oxacillin and
manuka honey restored oxacillin susceptibility to a MRSA strain
(Jenkins and Cooper, 2012b). Clindamycin and honey gave an
additive (approximately double) activity for all strains, except for
MRSA strain RPAH18, which remained resistant. In contrast, gen-
tamicin produced little to no additive effects with either honey for
all S. aureus strains. This agrees with a recent report where gen-
tamicin and manuka honey combinations had no effect against
FIGURE 1 | Sensitivity of Staphylococcus aureus strains to antibiotics
used alone and in combination with Manuka-type honeys assessed by
agar disk diffusion assay. Diameter (in mm) of zones of inhibition around
4 μg-impregnated antibiotic disks onTSA plates without honey (black bar),
and in presence of 5% sugar solution (blue bar), 5% manuka honey (purple
bar), or 5% Medihoney (red bar). Mean values are presented and error bars
indicate one SD. Asterisks above the honey-antibiotic combination treatments
indicate statistically signiﬁcant differences from the antibiotic treatment
alone, as determined by ANOVA analysis with a post hoc Dunnett’s test. Data
for rifampicin (top left) is copied with permission from Müller et al. (2013).
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an epidemic MRSA strain (EMRSA-15; Jenkins and Cooper,
2012a).
Sugar is considered to be an important antibacterial component
of honey (Allen et al., 1991), therefore possible additive effects of
sugar alone were also tested. None of the tested antibiotics in
combination with sugar (at equivalent concentrations to honey
used) showed any increase in the zones of inhibition of growth
for any of the tested strains (Figure 1), suggesting that the sugar
content of honey in these assays is unlikely to be responsible for
the additive effects observed.
HONEY AND ANTIBIOTICS SYNERGISTICALLY INHIBIT S. aureus
PLANKTONIC GROWTH AND BIOFILM FORMATION, BUT THIS VARIES
WITH THE ANTIBIOTIC AND STRAIN
The results above indicate that manuka honey interacts posi-
tively with most antibiotics to inhibit S. aureus growth. To test
whether these effects were synergistic, as opposed to just addi-
tive, checkerboard microdilution assays were performed. Both
planktonic growth and the degree of bioﬁlm formation on an
abiotic surface were tested with various concentrations of each
honey and each antibiotic alone, and in all possible pairwise
combinations (Table 2). For all S. aureus strains the type of
effect, including additive and synergistic effects for antimicro-
bial agents alone and in combination with honey, was identical
for both planktonic growth and bioﬁlm formation. Table 2 sum-
marizes the MBIC obtained from crystal violet checkerboard
assays for the four S. aureus strains along with the correspond-
ing FICI. No antagonism (FICI > 4) was observed with any
combination.
Manuka honey and Medihoney each had an MBIC of 8% (w/v)
for all of the S. aureus strains tested, including NCTC8325 and
both the MRSA (RPAH18, MW2) and non-MRSA (042273567)
clinical isolates (Table 2), consistent with our previous data
(Lu et al., 2014). Results for rifampicin were similar to those
observed in the agar diffusion assays, where all strains showed
increased sensitivity to rifampicin and honey when used in
combination compared to the single treatments alone, and
this interaction was found to be synergistic (FICI < 0.5).
For strains that were already sensitive to oxacillin (non-MRSA
strains NCTC8325 and 042-227-3567), synergistic effects were
observed between oxacillin and both honeys. Although resis-
tant strains (MRSA strains, RPAH18, and MW2) did not show
mathematically synergistic effects with the oxacillin and honey
combinations, both strains went from being clinically resistant
(MIC > 20 μg/mL) to sensitive (MIC < 0.06 μg/mL) to oxacillin
(based on EUCAST susceptibility breakpoints; EUCAST, 2014)
with the addition of honey. MW2 became sensitive in com-
bination with both manuka and Medihoney, while RPAH18
showed sensitivity only in combination with manuka honey
(Table 2).
Combinations of clindamycin with manuka and Medihoney
were synergistic against all S. aureus strains except MRSA strain,
RPAH18, which remained resistant. No synergistic effects were
observed with gentamicin, however, strains displayed increased
susceptibility to the combination of this antibiotic with either
honey, again with the exception of MRSA strain RPAH18, which
remained resistant (MIC > 20 μg/mL) to gentamicin.
DISCUSSION
To address the urgent problem of antibiotic resistance, this
study evaluated the antimicrobial activity of combinations of NZ
manuka-type honeys with four antibiotics commonly used to
treat S. aureus-related skin infections. We demonstrate increased
sensitivity to both antibiotics and manuka-type honeys when they
are used in combination, even when strains are clinically resistant
to a particular antibiotic; however, this depends on the antibi-
otic and on the S. aureus strain. For all tested S. aureus strains,
the rifampicin-honey combination is the most promising, with
synergistic inhibition observed for both planktonic growth and
bioﬁlm formation. Thus our work suggests that NZ manuka-type
honey has excellent potential as an alternative natural antimicro-
bial agent for use in combination therapy with rifampicin against
S. aureus-related skin infections.
Although quantiﬁable synergism, as measured by the FICI, was
not observed for every honey-antibiotic combinations tested in
this study, increased sensitivity was observed for most combina-
tions. For example, the MIC and MBIC of oxacillin, clindamycin,
and gentamycin decreased from three- to eightfold, when used in
combination with manuka-type honeys. Additionally, while the
MRSA strains were resistant to oxacillin beyond clinically achiev-
able concentrations (>20 μg/mL), when combined with the NZ
manuka-type honeys, susceptibility was reduced to within clin-
ically achievable peak plasma concentrations (e.g., <63 μg/mL;
Amsden, 2009). This overall, and at times dramatic, improve-
ment in antibiotic sensitivity when combined with honey sug-
gests the excellent potential of the use of manuka-type honeys
as an antibiotic adjuvant in combinational therapies to treat
antibiotic-resistant chronic wound infections.
Synergistic effects between oxacillin and manuka honey against
MRSA growth has been reported (Jenkins and Cooper, 2012b).
This was proposed to be due to the corresponding decreased tran-
scription of theMRSA-speciﬁc penicillin binding protein (PBP2A)
that has markedly reduced afﬁnity to β-lactams compared to
endogenous S. aureus PBP enzymes (de Lencastre et al., 2007;
Llarrull et al., 2009). Our results show, however, that negative reg-
ulation of PBP2A by manuka honey is unlikely to be the sole
mechanism responsible for the synergistic effect with β-lactams,
as strong synergism was also detected against non-MRSA strains,
which do not have the mecA gene (Sturenburg, 2009).
One of theways inwhich drug combinationswork is when both
drugs act on sequential or orthogonal steps of an essential physio-
logical pathway, achieving‘a like plus like’effect (Kalan andWright,
2011). Clindamycin and gentamicin inhibit bacterial cell growth
by targeting the 50S and the 30S subunits of the ribosome, respec-
tively (Schlunzen et al., 2001). Since NZ manuka-type honey alters
the levels of protein synthesis components, including ribosomal
proteins (Blair et al., 2009; Packer et al., 2012), the synergistic effect
of honey in combination with either of these antibiotics may be
due to this ‘like plus like’ effect on the protein synthesis pathway,
shutting it down more effectively.
Bactericidal drugs such asβ-lactams (e.g., oxacillin) and amino-
glycosides (e.g., gentamicin) contribute to cell deathby stimulating
hydroxyl radical formation via the Fenton reaction (Kohanski
et al., 2007). A major antibacterial component of honey, including
manuka, is hydrogen peroxide (White et al., 1963) and it acts
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via the production of hydroxyl radicals via the Fenton reaction
(Brudzynski and Lannigan, 2012). The enhanced sensitivity of
S. aureus to the bactericidal antibiotics upon addition of honey
could be at least partly due to an increase in hydroxyl radical
production. This might also explain why honey-oxacillin synergy
is observed with non-MRSA as well as MRSA strains; it is due to
enhanced hydroxyl radical production rather than, or in addition
to, any effect on PBP2A. However, we suspect other factors in
honey are responsible for the synergy because peroxide activity in
manuka-type honeys is not essential for the complete inhibition
of bacterial growth (Lu et al., 2013).
Interestingly, no increase in antibiotic susceptibility against
clindamycin and gentamicin was found with the clinical MRSA
isolate, RPAH18. The reason for this is unclear, but it may be due
to a different response by this strain toward the stresses induced
by the antibiotics and/or honey such as additional efﬂux systems
or other as yet uncharacterized physiological barriers that pre-
vent the entry, accumulation or action of these antibiotics. This
response by RPAH18 also indicates that the mechanism of honey-
antibiotic synergy is distinct from its mode of growth inhibition,
as all S. aureus strains tested to date, including many different
MRSA strains, are inhibited by honey to a very similar extent
(Blair and Carter, 2005). The implication of this strain variability
is that although honey may represent a good antibiotic adjuvant,
it may not always work. Dissection of the synergistic mechanism
between honey and antibiotics is necessary to understand this
strain variation. However, it should be noted that manuka-type
honeys remained effective at inhibiting growth and bioﬁlm for-
mation of RPAH18 when used alone at a slightly higher, easily
achievable concentration (>8%).
While honey may work well on its own to effectively treat
chronic wounds, our data also support the use of honey dressings
in situations where an additional systemic antibiotic is desirable,
for example in certain patients vulnerable to sepsis. Synergism and
improved sensitivity with combination treatments were obtained
with a low concentration (<8%) of manuka-type honey. This
is easily achieved since wound gel and honey dressings typically
contain >90% honey, and would still be effective after signiﬁcant
dilution with wound exudate. The Medihoney used in this study
is an existing commercially available and FDA-approved wound
dressing. As processed manuka honey, including gamma steril-
ization, Medihoney displayed the same level of effectiveness as
unprocessed manuka honey in preventing the growth and bioﬁlm
formation of S. aureus. Controlled clinical trials could therefore be
used to examine the value of manuka-based honey dressings both
alone or in combination with antibiotics in the effective treatment
of recalcitrant wounds. This is particularly promising as very few
new antibiotics are being developed, and the antibiotic resistance
problem is increasing, often with resistance developing in chronic
infected wounds prior to completion of therapy. In addition, top-
ical treatment of skin and chronic wound infections with honey
would target areas of the wound bed that a systemically admin-
istered antibiotic may not be able to enter, such as the necrotic
wound tissue. The overall effectiveness of NZ manuka-type hon-
eys and antibiotic combinations could represent a new model of
treatment for wound-associated infections, where the antibiotic
acts systemically entering from the bottom of the wound bed (as
well as functioning as a prophylactic for systemic infections), while
honey acts topically from the top of the wound. This approach
represents an immediate practical solution for the treatment of
difﬁcult to treat S. aureus-related infections.
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